Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

C Piette; S Suciu; E Clappier; Y Bertrand; S Drunat; S Girard; K Yakouben; G Plat; N Dastugue; F Mazingue; N Grardel; N van Roy; A Uyttebroeck; V Costa; O Minckes; N Sirvent; P Simon; P Lutz; A Ferster; C Pluchart; M Poirée; C Freycon; M-F Dresse; F Millot; C Chantrain; J van der Werff Ten Bosch; K Norga; C Gilotay; P-S Rohrlich; Y Benoit; H Cavé

doi:10.1038/leu.2017.289

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Leukemia. 2018 Jan;32(1):244-248. doi: 10.1038/leu.2017.289. Epub 2017 Sep 19.

Authors

C Piette¹, S Suciu², E Clappier^{3

4}, Y Bertrand⁵, S Drunat³, S Girard⁶, K Yakouben⁷, G Plat⁸, N Dastugue⁸, F Mazingue⁹, N Grardel⁹, N van Roy¹⁰, A Uyttebroeck¹¹, V Costa¹², O Minckes¹³, N Sirvent¹⁴, P Simon¹⁵, P Lutz¹⁶, A Ferster¹⁷, C Pluchart¹⁸, M Poirée¹⁹, C Freycon²⁰, M-F Dresse¹, F Millot²¹, C Chantrain²², J van der Werff Ten Bosch²³, K Norga²⁴, C Gilotay², P-S Rohrlich¹⁹, Y Benoit²⁵, H Cavé^{3

4}

Affiliations

¹ University Department of Pediatrics, Pediatric Onco-Hematology, CHR Citadelle, Liège, Belgium.
² EORTC Headquarters, Brussels, Belgium.
³ Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
⁴ Institut Universitaire d'Hématologie, Université Paris Diderot, Paris-Sorbonne-Cité, Paris, France.
⁵ Department of Pediatric Hematology, IHOP, Hospices Civils de Lyon and Claude Bernard Lyon University, Lyon, France.
⁶ Laboratory of Hematology, East Lyon University Hospital, Hospices Civils de Lyon, Lyon, France.
⁷ Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Service d'Immuno-Hématologie pédiatrique, Paris, France.
⁸ Department of Pediatric Onco-Hematology, Purpan University Hospital, Toulouse, France.
⁹ Department of Pediatric Hematology-Oncology, Lille University Hospital, Lille, France.
¹⁰ Center for Medical Genetics, Ghent University, Ghent, Belgium.
¹¹ Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium.
¹² Department of Pediatrics, Portuguese Oncology Institute, Porto, Portugal.
¹³ Department of Pediatric Onco-Hematology, Caen University Hospital, Caen, France.
¹⁴ Department of Pediatric Onco-Hematology, Montpellier University Hospital, Montpellier, France.
¹⁵ Department of Pediatric Onco-Hematology, Besançon University Hospital, Besançon, France.
¹⁶ Department of Hematology, Hautepierre University Hospital, Strasbourg, France.
¹⁷ Department of Pediatric Onco-Hematology, Hôpital Universitaire des Enfants Reine Fabiola (ULB), Brussels, Belgium.
¹⁸ Department of Pediatric Onco-Hematology, Reims University Hospital, Reims, France.
¹⁹ Department of Pediatric Onco-Hematology, Nice University Hospital, Nice, France.
²⁰ Department of Pediatric Onco-Hematology, Grenoble University Hospital, Grenoble, France.
²¹ Department of Pediatric Onco-Hematology, Poitiers University Hospital, Poitiers, France.
²² Department of Pediatrics, Clinique de l'Espérance, CHC, Liège, Belgium.
²³ Department of Pediatric Onco-Hematology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
²⁴ Pediatric Onco-Hematology Unit, Antwerp University Hospital, Antwerp, Belgium.
²⁵ Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium.

PMID: 29064485
DOI: 10.1038/leu.2017.289

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Agents / therapeutic use*
B-Lymphocytes / drug effects
Child
Child, Preschool
Core Binding Factor Alpha 2 Subunit / metabolism*
ETS Translocation Variant 6 Protein
Female
Humans
Infant
Male
Oncogene Proteins, Fusion / metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
Proto-Oncogene Proteins c-ets / metabolism*
Repressor Proteins / metabolism*

Substances

Antineoplastic Agents
Core Binding Factor Alpha 2 Subunit
Oncogene Proteins, Fusion
Proto-Oncogene Proteins c-ets
RUNX1 protein, human
Repressor Proteins